UBE2L6 Antibody

What is UBE2L6 and what are its primary functions in cellular processes?

UBE2L6 (also known as RIG-B, UBCH8, MGC40331) belongs to the E2 ubiquitin-conjugating enzyme family. This enzyme catalyzes the covalent attachment of ubiquitin to target proteins and shares structural similarities with the enzyme encoded by UBE2L3 gene . UBE2L6 functions in several critical cellular processes:

• Mediates the e6/e6-ap-induced ubiquitination of p53/tp53

• Plays a significant role in ISGylation, a post-translational modification process similar to ubiquitination

• Involved in type I interferon production and regulation of cytokine production

• Contributes to protein modification processes and binds to ISG15 protein

UBE2L6 is primarily localized in the cytoplasm and has been implicated in immune system regulation, particularly in the induction of interferon-alpha/beta pathways mediated by RIG-I/MDA5 .

What are the recommended Western blot protocols for UBE2L6 antibody?

For optimal Western blot results when using UBE2L6 antibody, researchers should follow these methodological guidelines:

• Sample preparation: Lyse cells in modified RIPA buffer (50 mM Tris/HCl pH 7.4, 150 mM NaCl, 0.25% sodium deoxycholate, 1% Igepal, 1 mM EDTA, with protease inhibitors including Pefabloc, Na₃VO₄, and NaF)

• Gel electrophoresis: Separate protein samples on NuPAGE 4-12% Bis/Tris gels or equivalent gradient gels

• Transfer: Electrophoretically transfer proteins onto PVDF membranes

• Antibody dilution: Use UBE2L6 antibody at a dilution range of 1:1,000-1:3,000, with a recommended starting dilution of 1:2,000

• Detection: Visualize using appropriate IR-DYE secondary antibodies for quantification on IR imaging systems

• Controls: Include β-actin as a loading control and potentially ISG15 as a functional verification control if studying the ISGylation pathway

The antibody has been validated through ELISA, Western blot, and immunohistochemistry analyses to ensure specificity and reactivity .

How should UBE2L6 antibody be stored and handled to maintain optimal activity?

To preserve antibody functionality and prevent degradation, researchers should adhere to these storage and handling procedures:

• For short-term storage (up to 1 month), maintain at 4°C

• For long-term storage, keep at -20°C

• Avoid repeated freeze-thaw cycles as they can degrade antibody quality and reduce specificity

• The antibody formulation typically contains 1mg/ml in PBS, pH 7.4, with 0.1% Sodium Azide as a preservative

• Under proper storage conditions, UBE2L6 antibody maintains stability for approximately 12 months at -20°C and 1 month at 4°C

Researchers should aliquot the antibody upon receipt to minimize freeze-thaw cycles if multiple experiments are planned over extended periods.

How can UBE2L6 antibody be utilized to investigate tuberculosis biomarkers?

UBE2L6 has demonstrated significant potential as a biomarker for tuberculosis (TB). Research approaches using UBE2L6 antibody for TB biomarker studies should consider:

Experimental design considerations:

• Compare UBE2L6 expression levels between TB patients and healthy controls using peripheral blood samples

• Perform ROC analysis to evaluate diagnostic efficiency

Performance metrics from current research:
UBE2L6 demonstrates strong diagnostic value for TB with the following parameters:

These values exceed the World Health Organization's minimum standard for TB diagnostic tools (75% sensitivity, 75% specificity) and approach the optimal ideal state (90% sensitivity, 90% specificity) .

Differential diagnosis applications:
UBE2L6 shows varying effectiveness in differentiating between TB types:

• Excellent for distinguishing pulmonary TB from healthy controls

• Limited utility for differentiating extrapulmonary TB from pulmonary TB (AUC: 0.621, 8.22% sensitivity, 4.68% specificity)

• Moderate effectiveness for distinguishing pulmonary TB from sarcoidosis (AUC: 0.747, 80.0% sensitivity, 67.3% specificity)

Researchers should pair UBE2L6 analysis with additional biomarkers like miR-146a-5p, which has also shown diagnostic potential for TB (AUC=0.791) .

What role does UBE2L6 play in leukemic cell differentiation, and how can this be studied experimentally?

UBE2L6 demonstrates significant involvement in leukemic cell differentiation, particularly in response to all-trans retinoic acid (ATRA) treatment. To investigate this role:

Experimental approach:

• Use cell line models such as:

  • NB4 acute promyelocytic leukemia (APL) cells and ATRA-resistant NB4R counterparts

  • HL60 AML cells and their ATRA-resistant subclone HL60R

• Measure UBE2L6 expression changes:

  • Quantitative real-time PCR (qPCR) relative to housekeeping genes (hPRT, HMBS, or ABL1)

  • Western blot analysis to assess protein levels

• Functional studies using shRNA knockdown:

  • Generate lentiviral vectors expressing shRNAs targeting UBE2L6

  • Recommended validated shRNAs: shUBE2L6_499 (NM_004223.3-499s1c1/TRCN0000007284) and shUBE2L6_1082 (NM_004223.3-1082s1c1/TRCN0000007281)

Key research findings:

• UBE2L6 expression increases significantly (180-fold) during ATRA-induced differentiation of NB4 cells but not in ATRA-resistant NB4R cells

• Similar induction (189-fold) occurs in HL60 cells but not in ATRA-resistant HL60R cells

• UBE2L6 expression is significantly lower in primary AML patient samples compared to mature granulocytes

• Knockdown of UBE2L6 impedes ATRA-mediated differentiation, suggesting a functional role in leukemic cell differentiation

These findings indicate that UBE2L6 plays a critical role in the ISGylation pathway during leukemic cell differentiation, and researchers should consider both UBE2L6 and ISG15 as important targets when studying ATRA-mediated differentiation mechanisms.

How can UBE2L6 antibody be employed to investigate drug resistance mechanisms in cancer therapy?

UBE2L6 has been implicated in platinum resistance mechanisms in ovarian cancer. Researchers investigating drug resistance using UBE2L6 antibody should consider:

Experimental design approach:

• Compare UBE2L6 expression between platinum-sensitive and platinum-resistant cancer cell lines using:

  • Western blotting with UBE2L6 antibody at 1:1,000-1:3,000 dilution

  • Immunohistochemistry at 1:50-1:100 dilution for tissue samples

• Perform functional studies:

  • Generate cisplatin-resistant cell lines through incremental exposure

  • Assess correlation between UBE2L6 expression and cisplatin IC50 values

  • Conduct knockdown or overexpression experiments to determine causative relationships

• Investigate associated molecular mechanisms:

  • Examine potential interactions with ABC transporter proteins, particularly ABCB6

  • Analyze UBE2L6's role in ubiquitination of drug resistance-related proteins

Recent research indicates that elevated UBE2L6 expression in cisplatin-resistant cells may contribute to drug resistance, potentially by modulating specific protein degradation pathways relevant to cellular sensitivity to platinum compounds .

What are the critical controls needed when using UBE2L6 antibody in immunoassays?

To ensure experimental validity and reliable interpretation of results when using UBE2L6 antibody, researchers should implement the following controls:

Essential controls for Western blot:

• Positive control: Cell lysates from ATRA-treated NB4 or HL60 cells (known to express high levels of UBE2L6)

• Negative control: Cell lysates from NB4R or HL60R cells (limited UBE2L6 expression)

• Loading control: β-actin antibody to normalize protein loading

• Specificity control: Pre-incubation of UBE2L6 antibody with recombinant UBE2L6 protein to verify binding specificity

Controls for immunohistochemistry:

• Tissue-specific positive and negative controls

• Isotype control using irrelevant mouse IgG2b antibody at equivalent concentration

• Secondary antibody-only control to assess non-specific binding

Controls for functional studies:

• Include both shRNA knockdown and scrambled/non-targeting shRNA controls

• When studying ISGylation, include parallel analysis of ISG15 (using anti-ISG15 antibody) to confirm pathway involvement

How can UBE2L6 protein-protein interactions be effectively studied using UBE2L6 antibody?

Investigating UBE2L6's interactions with other proteins is crucial for understanding its role in ubiquitination, ISGylation, and disease mechanisms. Recommended methodological approaches include:

Co-immunoprecipitation (Co-IP):

• Prepare cell lysates in non-denaturing buffer to preserve protein-protein interactions

• Immunoprecipitate using UBE2L6 antibody conjugated to protein G beads

• Elute bound proteins and analyze by Western blot for potential interacting partners

• Verify interactions through reciprocal Co-IP using antibodies against suspected binding partners

Proximity Ligation Assay (PLA):

• Fix and permeabilize cells on microscope slides

• Incubate with UBE2L6 antibody and antibody against potential interacting protein

• Apply species-specific PLA probes and perform ligation and amplification

• Analyze fluorescent signals indicating proximity (<40 nm) between proteins

Mass Spectrometry approaches:

• Perform immunoprecipitation with UBE2L6 antibody

• Process samples for mass spectrometry analysis

• Identify potential binding partners through database searching

• Validate key interactions using orthogonal methods

Based on current research, key interaction partners to investigate include:

• ISG15 and components of the ISGylation machinery

• E6/E6-AP complex components involved in p53 ubiquitination

• RIG-I/MDA5 pathway components in interferon response

• Proteins implicated in tuberculosis pathophysiology or drug resistance mechanisms

What are the challenges in interpreting UBE2L6 data across different experimental systems and disease models?

Researchers face several challenges when comparing UBE2L6 findings across different experimental systems and disease contexts:

Expression variability:

• UBE2L6 expression is highly inducible (up to 200-fold) by ATRA in leukemic cells

• It is regulated by type I interferons in tuberculosis models

• Expression patterns may differ substantially between cell lines, primary cells, and tissue samples

Functional context dependence:

• In tuberculosis, UBE2L6 inhibits apoptosis of Mycobacterium tuberculosis-infected macrophages

• In acute promyelocytic leukemia, UBE2L6 promotes ATRA-induced differentiation

• In ovarian cancer, UBE2L6 may contribute to cisplatin resistance

These apparently contradictory roles highlight the context-dependent nature of UBE2L6 function.

Methodological considerations for data reconciliation:

• Clearly define the experimental context (cell type, disease model, treatment conditions)

• Use multiple complementary techniques to assess UBE2L6 function

• Consider the broader signaling network and cellular environment

• Account for post-translational modifications that may affect UBE2L6 function

• Standardize quantification methods when comparing across studies

A systematic approach comparing UBE2L6 expression and function across multiple disease models using standardized methodologies would help resolve apparent contradictions and provide a more comprehensive understanding of this protein's context-specific roles.

How can UBE2L6 antibody be utilized in investigating the ISGylation pathway in immune responses?

The ISGylation pathway represents a post-translational modification system similar to ubiquitination but utilizing ISG15 instead of ubiquitin. UBE2L6 functions as the critical E2 conjugating enzyme in this pathway. Researchers can leverage UBE2L6 antibody to investigate this process through:

Methodological approaches:

• Dual immunofluorescence/immunohistochemistry:

  • Co-stain tissues or cells for both UBE2L6 and ISG15 to identify regions of active ISGylation

  • Analyze co-localization patterns through confocal microscopy

• ISGylated protein identification:

  • Immunoprecipitate with anti-ISG15 antibody followed by mass spectrometry

  • Use UBE2L6 antibody to confirm the presence of the conjugating enzyme in the ISGylation complex

• Immune response monitoring:

  • Track UBE2L6 expression changes following type I interferon stimulation

  • Correlate with ISGylation levels and specific immune response markers

Research indicates that UBE2L6 plays crucial roles in regulating cytokine production (p = 1.33E-12) and type I interferon production (p = 5.18E-06) . Its involvement in the immune system (p = 2.28E-11) and the RIG-I/MDA5-mediated induction of IFN-alpha/beta pathway suggests it serves as a key component in innate immune signaling .

What are the most promising techniques for studying UBE2L6 involvement in cancer progression and therapy resistance?

UBE2L6's emerging roles in cancer progression and therapy resistance warrant sophisticated research approaches:

Advanced experimental techniques:

• CRISPR/Cas9 gene editing:

  • Generate UBE2L6 knockout cell lines to assess functional consequences

  • Create point mutations in key catalytic residues to distinguish enzymatic from scaffolding functions

• Patient-derived xenograft (PDX) models:

  • Establish PDX models from platinum-sensitive and resistant tumors

  • Compare UBE2L6 expression levels using immunohistochemistry with UBE2L6 antibody

  • Test targeted therapies against UBE2L6 or its regulated pathways

• Single-cell analysis:

  • Perform single-cell RNA sequencing to identify cellular subpopulations with differential UBE2L6 expression

  • Use UBE2L6 antibody for CyTOF analysis to correlate with other markers of therapy resistance

• Combination therapy approaches:

  • Test whether UBE2L6 inhibition can resensitize resistant cells to platinum-based chemotherapy

  • Investigate synergistic effects with other targeted therapies

Research has already demonstrated elevated UBE2L6 expression in cisplatin-resistant cells, suggesting it contributes to drug resistance mechanisms . The established role of UBE2L6 in APL cell differentiation also indicates potential applications in differentiation therapy approaches beyond ATRA-sensitive leukemias .

How might UBE2L6 antibody be employed in developing novel diagnostic or therapeutic strategies?

UBE2L6's roles in tuberculosis, leukemia, and cancer therapy resistance position it as a promising target for novel diagnostic and therapeutic development:

Diagnostic applications:

• Tuberculosis diagnosis:

  • Develop point-of-care tests measuring UBE2L6 in blood samples

  • Current research demonstrates high diagnostic efficiency (AUC up to 0.985, sensitivity 97.8%, specificity 95.1%)

  • Combine with miR-146a-5p detection for improved accuracy

• Cancer therapy resistance prediction:

  • Create immunohistochemistry panels including UBE2L6 to predict platinum response

  • Develop liquid biopsy approaches measuring circulating UBE2L6 protein or gene expression

Therapeutic targeting strategies:

• Small molecule inhibitors:

  • Design selective UBE2L6 enzyme inhibitors to modulate ISGylation

  • Target UBE2L6 protein-protein interactions with specific binding partners

• Combination therapy approaches:

  • For platinum-resistant cancers, combine UBE2L6 inhibition with conventional chemotherapy

  • For leukemias with reduced UBE2L6 expression, enhance differentiation by upregulating UBE2L6

• RNA-based therapeutics:

  • Develop siRNA or antisense oligonucleotides targeting UBE2L6 for specific disease contexts

  • Design miRNA mimics of miR-146a-5p to modulate UBE2L6 expression in tuberculosis

The successful development of these approaches requires thorough validation of UBE2L6 antibodies for target engagement studies and careful consideration of context-dependent UBE2L6 functions across different disease models.

What are the key specifications researchers should verify when selecting a UBE2L6 antibody?

When selecting a UBE2L6 antibody for research applications, scientists should verify these critical specifications:

Antibody characteristics:

• Clone type: Monoclonal antibodies like Pk1H3AT offer higher specificity and batch-to-batch consistency compared to polyclonal alternatives

• Host species: Mouse-derived antibodies (e.g., Mouse Anti-Human Monoclonal) are commonly available

• Immunogen: Verify the immunogen used matches your research needs (e.g., recombinant human UBE2L6 amino acids 1-152)

• Isotype: For UBE2L6 antibodies, typical isotypes include Mouse IgG2b heavy chain with κ light chain

• Purification method: High-quality antibodies should undergo affinity purification (e.g., protein-G affinity chromatography)

• Formulation: Standard formulations contain approximately 1mg/ml in PBS (pH 7.4) with 0.1% Sodium Azide as preservative

Validation criteria:

• Validated applications (ELISA, Western blot, immunohistochemistry)

• Specificity testing against related E2 enzymes (particularly UBE2L3)

• Confirmation of reactivity with both native and denatured UBE2L6

• Batch-specific quality control data

How can researchers troubleshoot common issues with UBE2L6 antibody in experimental applications?

When encountering problems with UBE2L6 antibody experiments, researchers should implement these troubleshooting approaches:

Western blot issues:

Immunohistochemistry troubleshooting:

• High background:

  • Increase blocking time/concentration

  • Reduce primary antibody concentration

  • Perform additional washing steps

• Variable staining intensity:

  • Standardize fixation protocols

  • Use automated staining platforms

  • Implement image analysis software for quantification

• False negatives:

  • Test multiple antigen retrieval methods

  • Verify tissue fixation is compatible with epitope recognition

  • Use positive control tissues with known UBE2L6 expression

For experimental design optimization, researchers should consider the substantial induction of UBE2L6 expression by type I interferons and ATRA when designing positive controls and experimental timelines .

What novel roles for UBE2L6 are emerging in disease pathophysiology beyond current established functions?

While UBE2L6 has established roles in tuberculosis, leukemic cell differentiation, and platinum resistance, emerging research suggests broader implications:

Potential novel functions being explored:

• Autoimmune disease regulation:

  • UBE2L6's involvement in type I interferon pathways suggests potential roles in systemic lupus erythematosus and related autoimmune conditions

  • Research using UBE2L6 antibodies could help elucidate mechanisms of interferon dysregulation

• Viral infection responses:

  • ISGylation pathways mediated by UBE2L6 play critical roles in antiviral defense

  • Investigation using UBE2L6 antibodies may reveal specific viral targets of ISGylation

• Neurodegenerative disease mechanisms:

  • Protein quality control via ubiquitination is crucial in preventing neurodegeneration

  • UBE2L6's role in protein modification may extend to neurodegenerative disease contexts

• Metabolic regulation:

  • Potential roles in insulin signaling and metabolism through targeted protein degradation

  • UBE2L6 antibodies could help identify novel substrates in metabolic pathways

Future research should employ UBE2L6 antibodies in diverse disease models to expand our understanding of this enzyme's multifaceted roles in human health and disease.

How can computational approaches enhance UBE2L6 antibody research and target identification?

Integrating computational methods with experimental UBE2L6 antibody research offers powerful opportunities:

Computational approaches:

• Structure-based virtual screening:

  • Leverage UBE2L6 protein structure to identify potential small molecule inhibitors

  • Predict antibody binding epitopes to optimize immunoassay development

• Network analysis:

  • Map protein-protein interaction networks involving UBE2L6

  • Identify potential therapeutic targets in UBE2L6-related pathways

• Machine learning for biomarker discovery:

  • Develop algorithms integrating UBE2L6 expression with other biomarkers

  • Enhance diagnostic accuracy for tuberculosis beyond current metrics (AUC 0.985)

• Single-cell transcriptomics analysis:

  • Identify cellular subpopulations with unique UBE2L6 expression patterns

  • Correlate with disease progression markers across multiple conditions